Clinical Trial to Assess the Safety and Tolerability of Anti‐<scp>IL</scp> 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease
Luis Antonio Díaz(Pontificia Universidad Católica de Chile), Rohit Loomba(University of California San Diego), Tatiana Kisseleva(University of California San Diego), Christian Fulinara(University of California San Diego), Sonia Jain(University of Antwerp), Shravan Dave(University of California San Diego), Ricki Bettencourt(University of California San Diego), Jeremiah D. Momper(University of California San Diego), Susy M. Kim(University of California San Diego), Thuy Thi Thanh Pham(University of California San Diego), Raquel Carvalho‐Gontijo Weber(University of California San Diego), Catriona Jamieson(University of California San Diego), L. Richards(University of California San Diego), Grant G. Miller(University of California San Diego), Sheldon Morris(Medical University of Graz), Egbert Madamba(University of California San Diego), Wathnita Sarik(University of California San Diego), Feng He(Shanghai University of Traditional Chinese Medicine)
Cited by 4
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|Hepatology|2017|1.9k
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
|The Lancet Neurology|2022|1.5k